利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.022 秒)

    PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS
    1.
    发明申请
    PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS 审中-公开
    哌啶和哌嗪衍生物作为SMO拮抗剂

    公开(公告)号：US20130053396A1

    公开(公告)日：2013-02-28

    申请号：US13496958

    申请日：2010-09-21

    申请人： Philip Jones ,  Jesus Maria Ontoria Ontoria

    发明人： Philip Jones ,  Jesus Maria Ontoria Ontoria

    IPC分类号： C07D417/14 ,  A61P35/02 ,  A61P35/00 ,  C07D413/14 ,  A61K31/496

    CPC分类号： C07D413/04 ,  C07D417/04

    摘要： The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smo antagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract.

    摘要翻译： 本发明涉及作为Sonic Hedgehog途径的抑制剂，特别是Smo拮抗剂的式（I）化合物及其药学上可接受的盐或互变异构体。 因此，本发明的化合物可用于治疗与异常hedgehog途径活化相关的疾病，包括癌症，例如基底细胞癌，成神经管细胞瘤，前列腺，胰腺癌，乳腺癌，结肠癌，骨细胞和小细胞肺癌，以及癌症 上胃肠道

    Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP)
    7.
    发明授权
    Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) 失效
    作为聚（ADP-核糖）聚合酶（PARP）抑制剂的三环衍生物

    公开(公告)号：US08362030B2

    公开(公告)日：2013-01-29

    申请号：US12922270

    申请日：2009-03-13

    申请人： Raffaele Ingenito ,  Philip Jones ,  Laura Llauger Bufi ,  Jesus Maria Ontoria Ontoria ,  Rita Scarpelli

    发明人： Raffaele Ingenito ,  Philip Jones ,  Laura Llauger Bufi ,  Jesus Maria Ontoria Ontoria ,  Rita Scarpelli

    IPC分类号： A61K31/437 ,  C07D471/12

    CPC分类号： C07D471/06 ,  C07D471/16

    摘要： The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.

    摘要翻译： 本发明涉及作为聚（ADP-核糖）聚合酶（PARP）的抑制剂的式（I）化合物及其药学上可接受的盐或互变异构体，因此可用于治疗癌症，炎性疾病，再灌注损伤，缺血状况， 中风，肾衰竭，心血管疾病，心血管疾病以外的血管疾病，糖尿病，神经变性疾病，逆转录病毒感染，视网膜损伤，皮肤衰老和紫外线诱发的皮肤损伤，以及用于癌症治疗的化学或放射增敏剂。